Welcome.
Are you a patient or carer?

This information is intended solely for patients who have been prescribed a Chiesi product by a UK healthcare professional, and their carers. Please confirm below, or go back to the home page.

I am a patient or carer No, take me back

UK-RES-2101605 August 2021

Last updated: 17^th June 2021

Clenil^® Modulite^® (beclometasone) batch variation for all strengths (50/100/200/250mcg)

Chiesi is experiencing an increase in inhaler demand. In order to help meet this increased demand of inhalers, we have decided to release a Clenil batch variation for all strengths.

What can you expect from the batch variation of Clenil you have received?

The Clenil batch variation contains the same medication as before, and therefore requires no difference to how you manage your asthma.
The Clenil batch variation remains in the same type of inhaler device (pressurised metered dose inhaler; pMDI), and therefore requires no difference to the way you take your inhaler.
The only difference is that unlike Clenil inhalers that you may have received since September 2019, there is no dose indicator.

Please note: If you have been prescribed Clenil 100mcg, your inhaler may also have the following differences in appearance (see below):

The colours of the main body of the inhaler and mouthpiece protective cap are beige and yellow, respectively (instead of brown and beige, respectively).
You will not see 'Clenil^® Modulite^™ 100mcg Inhaler PREVENTER' embossed on the inhaler.

Other considerations:

You should check the dosage on the labelling of the outer package and canister of your Clenil inhaler prior to taking your inhaler to ensure that you have received the expected inhaler strength.

As usual, be sure to keep track of when you start to use your inhaler – each Clenil inhaler contains 200 doses of medication, so if you are taking two puffs of your inhaler twice a day, this means the inhaler will last for over a month.

If you use a Volumatic™ Spacer Device, you should continue to use it as usual.

Remember to clean your inhaler once a week. You will find instructions on how to do this on the package leaflet.

A downloadable version of this information is available here.

Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

UK-CLE-2100036 September 2021

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue

Go back

UK-RES-2101574 August 2021

How to use Clenil

Patient Information Leaflet

Frequently asked questions

What is a Patient Information Leaflet and why is it useful?

The Patient Information Leaflet (known as Package Leaflet or PIL) is the leaflet that is included in the pack with a medicine. The PIL is patient-friendly and contains information about taking and using the prescribed medicine.

View and download the Clenil patient information leaflet

Clenil 50 micrograms inhaler - Download Button

Clenil 100 micrograms inhaler - Download Button

Clenil 200 micrograms inhaler - Download Button

Clenil 250 micrograms inhaler - Download Button

Note: You will be diverted away from this website when you click on the link.

This website has been provided by Chiesi Limited to support patients, and carers of patients, prescribed Chiesi respiratory products. If you have not been prescribed Clenil and are looking for information on another Chiesi respiratory product please visit our homepage.

Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.